financetom
Business
financetom
/
Business
/
New York cannabis regulations invalidated by state judge
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
New York cannabis regulations invalidated by state judge
Apr 4, 2024 2:39 PM

(Reuters) - A New York state judge has invalidated most of the state's cannabis regulations in a case that challenged marijuana advertising rules.

New York Supreme Court Justice Kevin Bryant said in an order on Wednesday that the state had not justified its rulemaking process in a raft of regulations put forward by the New York Office of Cannabis Management governing licensing, business operations and marketing of cannabis.

The judge in Albany criticized the Office of Cannabis Management and the New York Cannabis Control Board's response to the lawsuit filed by cannabis website Leafly Holdings ( LFLY ), saying they presented no evidence or justification to explain how the regulations were developed.

Leafly ( LFLY ) had sued over a rule that barred dispensaries from advertising on third-party platforms.

"There is no indication that any evidence was actually placed before the administrative agency and there is no outline of the process that the agency followed when deliberating regarding the proposed regulations," the judge wrote.

A spokesperson for the New York Attorney General's office, which defended the regulations in court, directed questions about the ruling to the state Office of Cannabis Management. The Office of Cannabis Management did not immediately respond to a request for comment.

Leafly ( LFLY ) in a statement said it is important that licensed operators have access to advertising tools to help them succeed and that the company hopes the ruling "ultimately leads to a healthy, stable adult-use market in the state."

Jonathan Havens, a cannabis attorney in New York at law firm Saul Ewing who is not involved in the lawsuit, said if the ruling stands as is, it will have a significant and broad impact on the New York cannabis industry.

"It didn't strike down the entire program, but I find it challenging to understand how there can be a fully functioning program if this isn't immediately addressed," Havens said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Fortuna Mining Q2 Gold Production Increases, 2025 Production Guidance Unchanged
Fortuna Mining Q2 Gold Production Increases, 2025 Production Guidance Unchanged
Jul 9, 2025
06:58 AM EDT, 07/09/2025 (MT Newswires) -- Fortuna Mining ( FSM ) on Wednesday said second-quarter gold production from ongoing operations rose to 61,736 ounces from 56,000 ounces at its three operating mines in West Africa and Latin America. Gold equivalent production from ongoing operations dropped slightly to 71,229 ounces from 71,368 ounces. Fortuna, which completed the sale of the...
Exact Sciences Says Its Oncodetect Test to Detect Colorectal Cancer Gets Medicare Coverage
Exact Sciences Says Its Oncodetect Test to Detect Colorectal Cancer Gets Medicare Coverage
Jul 9, 2025
06:57 AM EDT, 07/09/2025 (MT Newswires) -- Exact Sciences ( EXAS ) said Wednesday that its Oncodetect molecular residual disease test has received Medicare coverage for serial use in patients with stage 2, 3 and resectable stage 4 colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period. The Oncodetect test is now covered by Medicare through...
JP Morgan CEO to Handelsblatt: we want to invest further in Germany
JP Morgan CEO to Handelsblatt: we want to invest further in Germany
Jul 9, 2025
BERLIN, July 9 (Reuters) - JP Morgan's CEO signalled that he was ready for the U.S. bank to invest in Germany, telling business daily Handelsblatt in an interview on Wednesday that the aim was to continue to grow. JP Morgan would absolutely invest in Germany, Jamie Dimon told the newspaper. He added: Our focus is not only on large companies,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved